Key Highlights

  • ROIV shares are trading up 18.01% to $41.22.
  • Pulmovant Subsidiary reported strong Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, presented at the ERS International Congress.
  • The drug hit its primary endpoint with a placebo-adjusted 56.3% reduction in pulmonary vascular resistance at Week 16, the largest PVR reduction ever reported in a randomized controlled pulmonary hypertension trial.
  • Secondary endpoint wins included a 35.2-meter improvement in six-minute walk distance and a 53.2% reduction in NT-proBNP, with benefits strengthening through Week 24 in exploratory analysis.
  • Jefferies reiterated a Buy rating and raised its price target to $52 from $42 following the data.

Shares Soar on a Record Pulmonary Vascular Resistance Reduction

Roivant Sciences (NASDAQ:ROIV) shares are surging after its Pulmovant subsidiary reported strong Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, presented at the ERS International Congress. The drug hit its primary endpoint with a placebo-adjusted 56.3% reduction in pulmonary vascular resistance at Week 16, described as the largest PVR reduction ever reported in a randomized controlled pulmonary hypertension trial.

Roivant operates a distinctive 'Vant' model, creating nimble subsidiaries to develop and commercialize individual drug candidates across a broad range of therapeutic areas, with a pipeline spanning immunology, dermatology, oncology, hematology, and rare diseases.

Secondary Endpoints Reinforce the Strong Data Set

Secondary endpoint wins included a 35.2-meter improvement in six-minute walk distance and a 53.2% reduction in NT-proBNP, a biomarker of cardiac stress, with benefits strengthening through Week 24 in exploratory analysis. That combination of primary and secondary endpoint strength has fueled today's rally.

Phase 3 Program Already Underway

Investors are also encouraged that the Phase 3 PHrontier study is already enrolling, providing a clear path toward a potential registrational filing. Roivant's broader pipeline includes approved topical treatment Vtama for psoriasis and atopic dermatitis, along with clinical-stage candidates batoclimab, brepocitinib, and IMVT-1402 targeting conditions including thyroid eye disease and myasthenia gravis.

Analyst Upgrade Reinforces Bullish Sentiment

Jefferies responded to the data by reiterating a Buy rating and raising its price target to $52 from $42, reinforcing bullish sentiment as shares trade near 52-week highs on Volume well above average. Continued enrollment progress in the Phase 3 PHrontier study will likely be the next catalyst investors watch for mosliciguat.